Generic and biosimilar medicines provider Sandoz, part of Swiss pharmaceutical company Novartis Pharma AG (SIX:NOVN) (NYSE:NVS), said on Friday that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn).
Dveloped by Polpharma Biologics, Tyruko is approved to treat all indications covered by the reference medicine Tysabri (natalizumab), offering a new option for managing relapsing forms of multiple sclerosis (MS) and Crohn's disease in adults.
It is the first and only FDA-approved biosimilar for relapsing forms of MS.
The FDA's approval was based on clinical studies which demonstrated Tyruko's parallel efficacy, safety and immunogenicity to the reference medicine.
Sandoz's collaboration with Polpharma Biologics, initiated in 2019, enables Tyruko's global commercialisation while Polpharma retains responsibility for its development and manufacturing. Sandoz holds the worldwide rights for distribution.
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US
Aurisco announces Yangzhou, China manufacturing site's successful FDA inspection
Teva Pharmaceuticals and Alvotech expand biosimilars partnership in the US
Sandoz to invest USD90m in Biosimilar Technical Development Center in Slovenia
Brenzavvy Now Available for the Treatment of Adults with Type 2 Diabetes
Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Dr. Reddy's rituximab biosimilar candidate undergoes regulatory review in the US, EU and UK
Grossman Named President and Chief Medical Officer at Coya Therapeutics
Endo International launches first generic version of Merck's Noxafil